Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group

The World Health Organization Classification of Skeletal Muscle Tumors in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group

(2015) Erin R. Rudzinski et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Myogenin, AP2β, NOS-1, and HMGA2 Are Surrogate Markers of Fusion Status in Rhabdomyosarcoma

(2014) Erin R. Rudzinski et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

RecurrentMYOD1mutations in pediatric and adult sclerosing and spindle cell rhabdomyosarcomas: Evidence for a common pathogenesis

(2014) Narasimhan P. Agaram et al.   GENES CHROMOSOMES & CANCER

A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations

(2014) Shinji Kohsaka et al.   NATURE GENETICS

Classification of Rhabdomyosarcoma and Its Molecular Basis

(2013) David M. Parham et al.   ADVANCES IN ANATOMIC PATHOLOGY

Dense Pattern of Embryonal Rhabdomyosarcoma, a Lesion Easily Confused With Alveolar Rhabdomyosarcoma

(2013) Erin R. Rudzinski et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Transactivating mutation of theMYOD1gene is a frequent event in adult spindle cell rhabdomyosarcoma

(2013) Karoly Szuhai et al.   JOURNAL OF PATHOLOGY

PAX-FOXO1fusion status drives unfavorable outcome for children with rhabdomyosarcoma: A children's oncology group report

(2013) Stephen X. Skapek et al.   PEDIATRIC BLOOD & CANCER

Results of the Intergroup Rhabdomyosarcoma Study Group D9602 Protocol, Using Vincristine and Dactinomycin With or Without Cyclophosphamide and Radiation Therapy, for Newly Diagnosed Patients With Low-Risk Embryonal Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group

(2011) R. Beverly Raney et al.   JOURNAL OF CLINICAL ONCOLOGY

Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803

(2009) Carola A.S. Arndt et al.   JOURNAL OF CLINICAL ONCOLOGY